Innoviva (INVA) Long-Term Deferred Tax (2011 - 2025)
Innoviva (INVA) reported Long-Term Deferred Tax of $8.0 million for Q3 2025, down 46.34% on a YoY basis from $14.9 million in Q3 2024, and down 38.27% quarter-over-quarter from $12.9 million in Q2 2025.
Innoviva (INVA) Long-Term Deferred Tax (2011 - 2025) Analysis & Trends
Innoviva has reported Long-Term Deferred Tax for 10 years, with the latest figure at $8.0 million in Q3 2025.
- For the quarter ending Q3 2025, Long-Term Deferred Tax fell 46.34% year-over-year to $8.0 million; the trailing twelve-month figure through Sep 2025 stood at $8.0 million (down 46.34% YoY), and the FY2025 full-year result was $8.0 million, down 46.34% from the prior year.
- Long-Term Deferred Tax for Q3 2025 stood at $8.0 million, down from $12.9 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $74.0 million in Q1 2021, with the low at $5.0 million in Q3 2023.
- Historically, Long-Term Deferred Tax has averaged $21.2 million across 5 years, with a median of $13.9 million in 2024.
- Annual changes were most pronounced in 2021 — Long-Term Deferred Tax slumped 81.52% — and 2024, when it jumped 200.38%.
- Innoviva's Long-Term Deferred Tax stood at $17.3 million in 2021, then jumped by 34.32% to $23.3 million in 2022, then sank by 78.72% to $5.0 million in 2023, then surged by 143.42% to $12.1 million in 2024, then sank by 33.78% to $8.0 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $8.0 million (Q3 2025), $12.9 million (Q2 2025), and $12.3 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Innoviva | 1.69 Bn | 1.08 Bn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 12.93 Mn |
| Mar 31, 2025 | 12.29 Mn |
| Dec 31, 2024 | 12.05 Mn |
| Sep 30, 2024 | 14.88 Mn |
| Jun 30, 2024 | 11.45 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 6.33 Mn |
| Jun 30, 2022 | 23.27 Mn |
| Mar 31, 2022 | 22.40 Mn |
| Dec 31, 2021 | 17.33 Mn |
| Sep 30, 2021 | 28.16 Mn |
| Jun 30, 2021 | 48.69 Mn |
| Mar 31, 2021 | 74.02 Mn |
| Dec 31, 2020 | 93.76 Mn |
| Sep 30, 2020 | 109.49 Mn |
| Jun 30, 2020 | 118.35 Mn |
| Mar 31, 2020 | 138.24 Mn |
| Dec 31, 2019 | 154.17 Mn |
| Sep 30, 2019 | 166.56 Mn |